Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | OGA | O60502 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20522305 | 0.78 | HTR2B (0.52) | KMT2AMEN1LMNAHDAC3HDAC4 | |
| SCHEMBL13521311 | 0.75 | CCNE1 (0.46) | OGASMN1; SMN2 | |
| SCHEMBL28531250 | 0.74 | KMT2A (0.67) | KMT2AMEN1LMNAATMSMN1; SMN2 | |
| SCHEMBL5782986 | 0.73 | CCNE1 (0.60) | KMT2AMEN1LMNATSHRHSD17B10 | |
| SCHEMBL20883053 | 0.72 | CCNE1 (0.60) | OGASMN1; SMN2RAB9A | |
| SCHEMBL16113250 | 0.70 | OGA (0.73) | OGASMN1; SMN2HTT | |
| SCHEMBL20522416 | 0.70 | CCNE1 (0.48) | SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27035859 | 0.69 | CCNE1 (0.47) | SMN1; SMN2 | |
| SCHEMBL20522288 | 0.69 | GPR119 (0.51) | MAPT | |
| SCHEMBL28224185 | 0.68 | ALDH1A1 (0.66) | KMT2AMEN1TP53L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110719910-B | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-3601269-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2020-02-05 | — | — | EP | disclosed |
| CN-110719910-A | Novel inhibitors | 前体生物药物股份公司 | 2020-01-21 | — | — | CN | disclosed |
| WO-2018178384-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | KMT2A 3101/4885MEN1 3715/4885LMNA 3585/4885 |
| US-20200377493-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | KMT2A 2829/4885MEN1 4443/4885LMNA 3291/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | KMT2A 2908/4885MEN1 4170/4885LMNA 3155/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | KMT2A 2772/4885MEN1 4216/4885LMNA 3549/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | KMT2A 2867/4885MEN1 4169/4885LMNA 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.